| Bone Metabolism and Diseases | Lifetime | 45 | JP 2 | 99.55 |
| Bone health and treatments | Lifetime | 90 | JP 2 | 99.48 |
| NF-κB Signaling Pathways | Lifetime | 123 | JP 19 | 98.51 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 331 | JP 9 | 98.57 |
| Spine and Intervertebral Disc Pathology | Lifetime | 604 | JP 71 | 98.24 |
| Bone and Joint Diseases | Lifetime | 264 | JP 11 | 97.78 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 546 | JP 33 | 97.25 |
| Osteoarthritis Treatment and Mechanisms | Lifetime | 615 | JP 36 | 97.38 |
| Orthopedic Infections and Treatments | Lifetime | 703 | JP 27 | 96.84 |
| Total Knee Arthroplasty Outcomes | Lifetime | 935 | JP 42 | 97.28 |
| Bone health and osteoporosis research | Lifetime | 713 | JP 29 | 96.77 |
| Spinal Fractures and Fixation Techniques | Lifetime | 897 | JP 104 | 96.83 |
| Cervical and Thoracic Myelopathy | Lifetime | 301 | JP 58 | 96.62 |
| Scoliosis diagnosis and treatment | Lifetime | 396 | JP 46 | 95.93 |
| Musculoskeletal synovial abnormalities and treatments | Lifetime | 968 | JP 75 | 90.49 |
| Spinal Hematomas and Complications | Lifetime | 512 | JP 93 | 87.86 |
| Surgical site infection prevention | Lifetime | 978 | JP 26 | 88.03 |
| Bone Metabolism and Diseases | 2021-2025 | 29 | JP 2 | 96.04 |
| Orthopaedic implants and arthroplasty | 2021-2025 | 338 | JP 17 | 95.76 |
| Total Knee Arthroplasty Outcomes | 2021-2025 | 335 | JP 16 | 96.26 |
| Bone and Joint Diseases | 2021-2025 | 116 | JP 12 | 92.45 |
| Knee injuries and reconstruction techniques | 2021-2025 | 314 | JP 23 | 94.47 |
| Bone health and osteoporosis research | 2021-2025 | 200 | JP 4 | 93.22 |
| Spine and Intervertebral Disc Pathology | 2021-2025 | 795 | JP 85 | 92.74 |
| Sarcoma Diagnosis and Treatment | 2021-2025 | 551 | JP 42 | 91.30 |
| Hip and Femur Fractures | 2021-2025 | 503 | JP 15 | 89.80 |
| Scoliosis diagnosis and treatment | 2021-2025 | 309 | JP 39 | 90.73 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 713 | JP 40 | 90.37 |
| Foot and Ankle Surgery | 2021-2025 | 387 | JP 23 | 89.07 |
| Lower Extremity Biomechanics and Pathologies | 2021-2025 | 584 | JP 46 | 86.91 |
| Bone health and treatments | 2021-2025 | 411 | JP 45 | 83.38 |
| Tendon Structure and Treatment | 2021-2025 | 683 | JP 34 | 83.27 |
| Hip disorders and treatments | 2021-2025 | 646 | JP 61 | 82.63 |
| Neurofibromatosis and Schwannoma Cases | 2021-2025 | 515 | JP 37 | 78.68 |
| Cardiac tumors and thrombi | 2021-2025 | 529 | JP 53 | 76.34 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 658 | JP 21 | 71.77 |
| Bone Tumor Diagnosis and Treatments | 2021-2025 | 853 | JP 79 | 74.46 |
| Surgical site infection prevention | 2021-2025 | 595 | JP 23 | 69.55 |
| Cervical and Thoracic Myelopathy | 2021-2025 | 790 | JP 109 | 73.74 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 469 | JP 42 | 68.64 |
| Connective tissue disorders research | 2021-2025 | 735 | JP 55 | 67.43 |
| Soft tissue tumor case studies | 2021-2025 | 575 | JP 45 | 58.26 |
| Musculoskeletal synovial abnormalities and treatments | 2021-2025 | 989 | JP 79 | 53.85 |
| NF-κB Signaling Pathways | 2021-2025 | 853 | JP 49 | 31.68 |